PF-Atlas › Clinical Trials › NCT03125395

A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

LUM/IVA · Phase 3

Registry ID
NCT03125395
Phase
Phase 3
Status
Completed
Drug / intervention
LUM/IVA
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2017-05-12
Enrollment
57
Locations
20

About this trial

A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for F508del.

View NCT03125395 on ClinicalTrials.gov →

Explore related

All LUM/IVA trialsAll IPF trials

Related trials

LUM/IVA — NCT02875366LUM/IVA — NCT02797132LUM/IVA — NCT03061331
Medical disclaimer. This page summarizes public trial data for NCT03125395 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.